Information Technology

AIML Partners with Guerilla Capital for Enhanced Investor Relations

Last Updated:
Reading Time
2 min

AI/ML Innovations Inc. (CSE:AIML) has announced its engagement of Guerilla Capital for a comprehensive suite of investor relations services aimed at bolstering communications and outreach activities. This strategic partnership comes at a significant time as the company focuses on advancing its initiatives in digital health technology.

#Details of the Engagement

The collaboration with Guerilla Capital will commence immediately and is set for an initial duration of 12 months, with the possibility for extension based on the outcomes of the engagement. The financial arrangement totals Cdn$120,000, comprised of an upfront payment of Cdn$30,000, followed by quarterly installments of Cdn$30,000.

#Purpose and Goals

By leveraging Guerilla Capital's expertise in investor relations, AIML aims to enhance its visibility in the market and foster a stronger connection with its investors. The company anticipates that these efforts will not only improve investor confidence but also effectively communicate its advancements in artificial intelligence and neural networks.

#Company Background

AI/ML Innovations Inc. operates at the forefront of digital health innovation, utilizing cutting-edge technologies to convert complex biometric data into valuable clinical insights. This capability supports earlier diagnosis and personalized treatment plans, ultimately leading to improved patient care.

#Termination Clause

AIML retains the option to terminate the agreement with Guerilla Capital after the initial three months if it assesses the partnership's effectiveness as needing reevaluation.

#Conclusion

As AIML embarks on this collaborative journey with Guerilla Capital, stakeholders will be keen to observe the developments that arise from this engagement, particularly how it shapes the company’s investor relations strategy in the competitive landscape of technology-driven health solutions.

#Key Takeaways

  • AIML has engaged Guerilla Capital for investor relations to enhance communications and outreach.
  • The contract is valued at Cdn$120,000 over a 12-month initial term.
  • An upfront payment of Cdn$30,000 is followed by quarterly payments.
  • The engagement can be terminated after the first three months if necessary.
  • AIML focuses on integrating artificial intelligence in digital health for improved clinical insights.

Original source: Read original article

Frequently Asked Questions

AIML has engaged Guerilla Capital to enhance its communications and investor outreach efforts, which may result in improved investor relations and potentially a stronger market presence.
The total fee for Guerilla Capital's services is Cdn$120,000, with an initial upfront payment of Cdn$30,000. This structured payment plan reflects a strategic investment in investor relations.
The engagement is set for an initial term of 12 months, which indicates AIML's commitment to strengthening its investor communications over a significant period.
Yes, AIML has the option to terminate the engagement after the initial three months, allowing for flexibility while assessing the effectiveness of the partnership.
AIML is at the forefront of digital health technology, focusing on artificial intelligence and neural networks to provide actionable insights from biometric data. This positions the company well within a growing and essential industry.
AIML's shares are traded on multiple exchanges including the Canadian Securities Exchange, the OTCQB Venture Market, and the Frankfurt Stock Exchange, offering diverse accessibility to global investors.
As with any innovative technology company, AIML faces risks related to product implementation and regulatory approvals. However, addressing these challenges effectively can lead to substantial growth opportunities.
Investors can access detailed information about AIML's operations and financials through its website and filed documents at www.sedarplus.ca, which is beneficial for informed investment decisions.